A Phase 1b Dose-finding, Pharmacokinetic and Pharmacodynamic Study of NVX-108 Combined With Radiation and Temozolomide in Patients With Newly-diagnosed Glioblastoma Multiforme
Phase of Trial: Phase I
Latest Information Update: 04 Mar 2019
Price : $35 *
At a glance
- Drugs Perflenapent (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Adverse reactions
- Sponsors NuvOx Pharma
- 29 Sep 2017 According to National Cancer Institute media release, Status changed from active, no longer recruiting to completed.
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 22 Sep 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2017.